|
GB201820470D0
|
|
Antifolate-carrying nanoparticles and their use in medicine
|
|
GB201820471D0
|
|
Nanoparticle-based therapy of inflammatory disorders
|
|
GB201819430D0
|
|
Therapeutic compounds, nanoparticles and uses thereof
|
|
GB201711758D0
|
|
Pharamaceutical formulations
|
|
WO2017167837A1
|
|
Cyclodextrin-panobinostat adduct
|
|
GB201701745D0
|
|
Nanoparticle-based liver-targeting therapy and imaging
|
|
GB201610440D0
|
|
Pharmaceutical formulations
|
|
US2018177891A1
|
|
Nanoparticle-Based Antigen Specific Immunotherapy
|
|
GB201603358D0
|
|
Nanoparticle production
|
|
EP3237016A1
|
|
Nanoparticles and their use in cancer therapy
|
|
EP3217958A1
|
|
Sustained release encapsulated nanoparticles
|
|
GB201513103D0
|
|
Nanoparticle-based liver-targeting therapy and imaging
|
|
EP2964263A1
|
|
Nanoparticle peptide compositions
|
|
EP2964262A1
|
|
Nanoparticle peptide compositions
|
|
GB201401708D0
|
|
Nanoparticle glucagon compositions
|
|
GB201401706D0
|
|
Nanoparticle-insulin and insulin analogue compositions
|
|
GB201303787D0
|
|
Nanoparticle peptide compositions
|
|
GB201303771D0
|
|
Nanoparticles peptide compositions
|
|
GB201302427D0
|
|
Nanoparticle delivery compositions
|
|
GB201301991D0
|
|
Permeation enhanced active-carrying nanoparticles
|
